Cleo Diagnostics Ltd
COV
Company Profile
Business description
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company’s first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
Contact
480 Collins Street
Level 2
MelbourneVIC3000
AUST: +61 396140600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,543.70 | 34.10 | -0.40% |
| CAC 40 | 7,431.04 | 59.24 | -0.79% |
| DAX 40 | 20,214.79 | 102.31 | -0.50% |
| Dow JONES (US) | 41,938.45 | 696.75 | -1.63% |
| FTSE 100 | 8,248.49 | 71.20 | -0.86% |
| HKSE | 19,064.29 | 176.60 | -0.92% |
| NASDAQ | 19,161.63 | 317.25 | -1.63% |
| Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
| NZX 50 Index | 12,895.98 | 47.76 | -0.37% |
| S&P 500 | 5,827.04 | 91.21 | -1.54% |
| S&P/ASX 200 | 8,294.10 | 35.10 | -0.42% |
| SSE Composite Index | 3,168.52 | 42.87 | -1.33% |